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independent prognostic predictor for patients with
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Chengcheng Gao, Tianheng Ma, Liqun Pang and Rui Xie*Abstract
Objective: p21-activated kinase (PAK) 2, as a member of the PAK family kinases, is involved in a number of hallmark
processes including cell proliferation, survival, mitosis, apoptosis, motility and angiogenesis. However, the clinical
significance of the activation of PAK2 in human gastric cancer has not been fully elucidated. The aim of this study
was to investigate whether PAK2 expression and its phosphorylation status are correlated with tumor progression
and prognosis in gastric cancer.
Methods: Expression patterns and subcellular localizations of PAK2 and Ser20-phosphorylated PAK2 (pSer20PAK2)
in 82 gastric cancer patients were detected by immunohistochemistry.
Results: Both PAK2 and pSer20PAK2 immunostainings were localized in the cytoplasm of tumor cells of gastric
cancer tissues. Compared with the normal gastric mucosa, the expression levels of PAK2 and pSer20PAK2 proteins
were both significantly increased (both P < 0.001). Additionally, the patients displaying the over-expression of PAK2
and pSer20PAK2 proteins were dramatically associated with unfavorable clinicopathologic variables including higher
tumor depth (P = 0.022 and 0.036, respectively), greater extent of lymph node metastasis ((P = 0.022 and 0.036,
respectively), positive distant metastasis (P = 0.025 and 0.038, respectively) and advanced tumor stage (P = 0.018 and
0.031, respectively). Moreover, the patients overexpressing PAK2 and pSer20PAK2 proteins have poor overall survival
rates relative to those without overexpression of these proteins. Furthermore, cox multi-factor analysis showed that
PAK2 (p = 0.012) and pSer20PAK2 (p = 0.010) were independent prognosis factors for human gastric cancer.
Conclusion: Our data suggest for the first time that PAK2 activation may be associated with advanced tumor
progression and poor prognosis of gastric cancer.
Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1236344107120406.
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Gastric cancer is one of the most common neoplasms in
digestive system with highly malignant and a poor progno-
sis worldwide, especially in Asia and Africa [1]. It tends to
be associated with lymph node metastasis, peritoneal dis-
semination, and hematogenous metastasis. Despite the ad-
vancement of surgical technique and the improvement of
anticancer drugs in recent years, gastric cancer is still a
leading cause of cancer-related deaths and the 5-year* Correspondence: gao.jsha@gmail.com
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unless otherwise stated.survival rate is approximately 20% [2]. Especially in China,
the morbidity of gastric cancer has reached to second with
3,621,000 new cases, whilst the mortality rate ranked third
with the proportion of 14.33% annually [3]. It has been
demonstrated that the depth of tumor invasion, peritoneal
dissemination, hepatic metastasis, and lymph node metas-
tasis are significant factors in determining prognosis [4].
Since tumor invasion and metastasis are very complicated
and continuous processes involving multiple steps, regu-
lated at the molecular level by adhesion molecules, protein
catabolic enzymes, cellular growth factors, and various an-
giogenic factors, it is extremely necessary to identify novel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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in tumor development and metastasis in order to predict
prognosis and improve therapeutic strategies for patients
with gastric cancer.
The p21-activated kinases (PAKs) are a family of serine/
threonine protein kinases, which were initially identified
as binding partners of the Rho GTPases Cdc42 and Rac1
[5]. The PAK family includes six isoforms (PAK1-6) which
play a crucial role in a variety of physiological processes
such as motility, survival, mitosis, apoptosis, and hormone
signaling [6]. The PAKs are divided into two groups, group
I (PAKs 1–3) and group II (PAKs 4–6) based on structural
and functional similarities: group I PAKs exist in an in-
active homodimer maintained by interactions between the
autoinhibitory domain (AID) and kinase domain of PAK
monomers; group II PAKs also bind Rac and Cdc42, but
they lack an AID, exist as active monomers, and have not
been reported to have a scaffolding function [7]. Recent
studies have demonstrated that PAKs are overexpressed,
hyperactivated or amplified in several human cancers and
their role in cell transformation make them attractive
therapeutic targets [8]. Especially, PAK2, which has an
overall 76% homology with PAK1 and 96% homology in
the kinase domain, has a dual role in both cell survival
and cell death pathways. It is widely distributed through-
out the body and is not only activated by binding with the
small G protein complex Cdc42/Rac, but it is also cleaved
and activated by caspase-3 and similar proteases [9]. Full
length PAK2 is autophosphorylated at eight sites including
Ser20, Ser139, Ser141, Ser144, Ser192, Thr402, Thr421
and Thr423, and then activated [9]. Accumulating evi-
dence indicates that PAK2 are either up-regulated or
hyperactivated in a variety of human cancers, including
ovarian cancer [10] and breast cancer [11]. PAK2 plays an
important role in tumor aggressiveness, but its involve-
ment in gastric cancer has not yet clear. The aim of this
study was to investigate whether PAK2 expression and its
phosphorylation status are correlated with tumor progres-
sion and prognosis in gastric cancer.
Materials and methods
Patients and tissue samples
Eighty-two patients with gastric cancer (56 males and 26 fe-
males), underwent gastrectomy with lymph node dissection
between 1992 and 2006 at Department of Gastroenterology
were selected in this study. The patients ranged in age from
22 to 88 years (mean 65 years). None of these patients
underwent endoscopic mucosal resection, palliative resec-
tion, or preoperative chemotherapy, or had synchronous or
metachronous multiple cancer in other organs.
Clinicopathological findings were based on the criteria
of the tumor node metastasis (TNM) classification of the
International Union against Cancer [9]. Histopathological
types of gastric cancer were classified into two types,intestinal type and diffuse type. The intestinal type was
further classified into three differentiated types: well-
differentiated (tub1), moderately differentiated (tub2), and
papillary differentiated (pap); and the diffuse type was clas-
sified into two undifferentiated types: diffuse-adherent
(por1) and diffuse-scattered (tub2).
All patients were followed up after discharge, with X-ray
examination and tumor marker assays (carcinoembryonic
antigen and carbohydrate antigen 19–9) performed every
1–3 months, computed tomography performed every 3–
6 months, and ultrasonography performed every 6 months.
Endoscopic examinations were performed when necessary.
Postoperative follow-up data were obtained from all pa-
tients, with a median follow-up period of 36 months
(range 1–138 months).
This study was approved by the Research Ethics Commit-
tee of Huai’an No.1 Hospital, Affiliated to Nanjing Medical
University, Huai'an, Jiangsu, China. Informed consent was
obtained from all of the patients. All specimens were han-
dled and made anonymous according to the ethical and
legal standards.
Immunohistochemistry analysis
Immunohistochemical study for PAK2 and pSer20PAK2
was performed on formalin-fixed, paraffin-embedded, 4-
μm-thick tissue sections using the avidin-biotin-peroxidase
complex method. In brief, the sections were deparaffinized
and dehydrated using a graded series of ethanol solutions.
Endogenous peroxidase activity was halted through the ad-
ministration of 0.3% hydrogen peroxidase and methanol for
20 min. After having been rinsed in phosphate-buffered sa-
line (PBS), the tissue sections were processed in a 0.01 M
citrate buffer (pH 6.0) inside a heat-resistant plastic con-
tainer. Sections were then irradiated in a domestic micro-
wave oven for 20 min. After microwave irradiation, the
slides were allowed to cool at room temperature. The fol-
lowing antibodies were applied as the primary anti-
bodies: rabbit polyclonal to PAK2 (#ab45426, Abcam,
Cambridge, UK) and rabbit polyclonal to PAK2 (phos-
pho S20) (#ab59359, Abcam, Cambridge, UK). The sec-
tions were incubated with the primary antibody overnight
at 4°C followed by the secondary antibody. The results
were visualized with diaminobenzidine. In each immuno-
histochemistry run, matched negative controls were
stained without primary antibody.
Following a hematoxylin counterstaining, immuno-
staining was scored by two independent experienced pa-
thologists, who were blinded to the clinicopathological
parameters and clinical outcomes of the patients. The
scores of the two pathologists were compared and any dis-
crepant scores were treated through re-examining the
stainings using a multi-headed microscope with both pa-
thologists simultaneously to achieve a consensus score.
Expression of PAK2 and pSer20PAK2 were respectively
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epithelial tissues located distant from the tumor. The
number of positive-staining cells showing immunoreactiv-
ity on the cytoplasm for both PAK2 and pSer20PAK2 in
ten representative microscopic fields was counted and the
percentage of positive cells was calculated. The percentage
scoring of immunoreactive tumor cells was as follows: 0
(0%), 1 (1-10%), 2 (11-50%) and 3 (>50%). The staining in-
tensity was visually scored and stratified as follows: 0
(negative), 1 (weak), 2 (moderate) and 3 (strong). A final
immunoreactive score (IRS) was obtained for each case by
multiplying the percentage and the intensity score. The
median of the IRS value was used as the cutoff value to
divide the patients into high and low expression groups of
PAK2 and pSer20PAK2 proteins, respectively.
Statistical analysis
The software of SPSS version12.0 for Windows (SPSS
Inc, IL, USA) and SAS 9.1 (SAS Institute, Cary, NC) was
used for statistical analysis. The Kaplan-Meier method
was used for survival analysis, and differences in survival
were estimated using the log-rank test. Prognostic factors
were examined by univariate and multivariate analyses
(Cox proportional hazards regression model). Differences
were considered statistically significant when p was less
than 0.05.
Results
Overexpression of PAK2 and pSer20PAK2 in human
gastric cancer tissues
Expression patterns and subcellular localizations of PAK2
and pSer20PAK2 in gastric cancer and normal gastric mu-
cosa were detected by immunohistochemistry. As shown
in Figure 1, both PAK2 and pSer20PAK2 immunostainings
were localized in the cytoplasm of tumor cells of gastric
cancer tissues. Compared with the normal gastric mucosa,
the expression levels of PAK2 (IRS for gastric cancer vs.
normal gastric mucosa: 5.62 ± 1.93 vs. 2.33 ± 0.68, P <
0.001) and pSer20PAK2 (IRS for gastric cancer vs. normalFigure 1 Immunohistochemical stainings of PAK2 (A) and pSer20PAK
pSer20PAK2 immunostainings were localized in the cytoplasm of tumor cegastric mucosa: 5.99 ± 2.06 vs. 2.27 ± 0.61, P < 0.001) pro-
teins were both significantly increased. Of 82 patients with
gastric cancer, 62 (75.61%) and 69 (84.15%) were highly
expressed PAK2 and pSer20PAK2, respectively.
Association of PAK2 and pSer20PAK2 expression with the
clinicopathological characteristics of human gastric
cancer
Table 1 summarized the association of PAK2 and pSer20-
PAK2 expression with the clinicopathological characteris-
tics of human gastric cancer. The patients displaying the
over-expression of PAK2 and pSer20PAK2 proteins were
dramatically associated with unfavorable clinicopathologic
variables including higher tumor depth (P = 0.022 and
0.036, respectively), greater extent of lymph node metasta-
sis (P = 0.022 and 0.036, respectively), positive distant me-
tastasis (P = 0.025 and 0.038, respectively) and advanced
tumor stage (P = 0.018 and 0.031, respectively).
Overexpression of PAK2 and pSer20PAK2associate with
unfavorable prognosis in human gastric cancer
No patient died of postoperative complications within
30 days at the beginning of the study period. The 5-year
survival rates of patients with high PAK2 and pSer20PAK2
expression were respectively 58.01% and 57.97%, whereas
the rates for patients with low PAK2 and pSer20PAK2 ex-
pression were respectively 79.03% and 79.71%. Statistical
analysis showed that the 5-year survival in patients with
high PAK2 and pSer20PAK2 expressions were both signifi-
cantly shorter than those with low expressions (both P =
0.001; Figure 2).
Table 2 shows the univariate and multivariate analyses
of factors related to patient prognosis. The univariate ana-
lysis showed that the following factors were significantly
related to postoperative survival: depth of tumor invasion
(P < 0.001), lymph node metastasis (P < 0.001), venous in-
vasion (P < 0.001), PAK2 expression (P = 0.001) and
pSer20PAK2 expressions (P = 0.001). Multivariate regres-
sion analysis indicated that PAK2 expression (P = 0.01),2 (B) proteins in the gastric cancer tissues (×400). Both PAK2 and
lls of gastic cancer tissues.
Table 1 Correlations of PAK2 and pSer20PAK2 expression with the clinicopathological features of primary gastric cancer
Features No.
of cases
PAK2 expression P pSer20PAK2 P
High (%) Low (%) High (%) Low (%)
Age (years) 82 65.32 ± 11.06 64.59 ± 11.88 NS 65.17 ± 11.29 64.99 ± 11.81 NS
Gender
Male 56 42 (75.00) 14 (25.00) NS 47 (83.93) 9 (16.07) NS
Female 26 20 (76.92) 6 (23.08) 22 (84.62) 4 (15.38)
Histopathological type
Intestina type
pap 3 2 (66.67) 1 (33.33) NS 2 (66.67) 1 (33.33) NS
tub1 19 15 (78.95) 4 (21.05) 16 (84.21) 3 (15.79)
tub2 22 16 (72.73) 6 (27.27) 18 (81.82) 4 (18.18)
Diffuse type
por1 12 8 (66.67) 4 (33.33) NS 10 (83.33) 2 (16.67) NS
por2 26 21 (80.77) 5 (19.23) 23 (88.46) 3 (11.54)
Tumor depth (pT)
pT1 ~ pT2 62 42 (67.74) 20 (32.26) 0.022 49 (79.03) 13 (20.97) 0.036
pT3 ~ pT4 20 20 (100.00) 0 (0) 20 (100.00) 0 (0)
Lymph node metastasis (pN)
pN0 ~ pN1 66 46 (69.70) 20 (30.30) 0.022 53 (80.30) 13 (19.70) 0.036
pN2 ~ pN3 16 16 (100.00) 0 (0) 16 (100.00) 0 (0)
Distant metastasis (pM)
pM0 76 56 (73.68) 20 (26.32) 0.025 63 (82.89) 13 (17.11) 0.038
pM1 6 6 (100.00) 0 (0) 6 (100.00) 0 (0)
pStage
I ~ II 59 39 (66.10) 20 (33.90) 0.018 46 (77.97) 13 (33.90) 0.031
III ~ IV 23 23 (100.00) 0 (0) 23 (100.00) 0 (0)
Lymphatic invasion
Negative 35 26 (74.29) 9 (25.71) NS 29 (82.86) 6 (17.14) NS
Positive 47 36 (74.60) 11 (25.40) 40 (85.11) 7 (14.89)
Venous invasion
Negative 58 42 (72.41) 16 (17.59) NS 49 (84.48) 9 (15.52) NS
Positive 24 20 (83.33) 4 (16.67) 20 (83.33) 4 (16.67)
Hematogenous recurrence
Negative 72 55 (76.39) 17 (23.61) NS 61 (84.72) 11 (15.28) NS
Positive 10 7 (70.00) 3 (30.00) 8 (80.00) 2 (20.00)
Peritoneal recurrence
Negative 72 55 (76.39) 17 (23.61) NS 61 (84.72) 11 (15.28) NS
Positive 10 7 (70.00) 3 (30.00) 8 (80.00) 2 (20.00)
Note: ‘NS’ refers to ‘no significant’.
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0.002) and lymph node metastasis (P < 0.001) were inde-
pendent prognostic factors.
Discussion
Gastric cancer patients with the same tumor stage present
different clinical courses and have different prognosis.This heterogeneity is present at the molecular level and
has a genetic predisposition to it. An increasing number of
molecular markers identified by several research groups to
diagnose patients with gastric cancer at an early stage and
to screen the patients with a high risk of developing recur-
rence or metastases from those patients with a low risk
[12-17]. However, the fundamental molecular mechanism
Figure 2 Postoperative 5-year survival curves of patients according to the expression patterns of PAK2 (A) and pSer20PAK2 (B)
proteins. Statistical analysis showed that the 5-year survival in patients with high PAK2 and pSer20PAK2 expressions were both significantly
shorter than those with low expressions (both P = 0.001).
Gao et al. Diagnostic Pathology 2014, 9:55 Page 5 of 6
http://www.diagnosticpathology.org/content/9/1/55underlying tumorigenesis and tumor progression in gastric
cancer is poorly understood and has not been fully eluci-
dated. Thus, it is of great significance to identify effective
indicators to better understand the biological basis for the
survival of gastric cancer patients in order to provide im-
portant clinically relevant insights into disease manage-
ment. In the current study, we demonstrated that the
expression levels of PAK2 and pSer20PAK2 proteins were
significantly higher in gastric cancer than in normal gastric
mucosa. There were significant associations between PAK2,
pSer20PAK2 expression and aggressive clinicopathological
features. The overexpression of PAK2 and pSer20PAK2
proteins were both identified as independent prognostic
factors in gastric cancer. These findings suggest that the ac-
tivation of PAK2 may be a valuable diagnostic marker and
therapeutic target for gastric cancer. To the best of our
knowledge, this is the first report to determine the correl-
ation between PAK2, pSer20PAK2 expression and clinical
factors in gastric cancer.
The primary hallmark of cancer is the growth of tumor
cells and the ability to form tumors [18]. PAKs were ori-
ginally shown to be important for transformation in exper-
iments where a kinase dead mutant of PAK was expressedTable 2 Univariate and multivariate analyses of prognostic fa
Independent factors Univariate P Multiva
Tumor depth (pT)
pT1 and pT2/pT3 and pT4 <0.001 0.002








Note: ‘NS’ refers to ‘no significant’.in fibroblasts together with an oncogenic Ras mutant
[19]. Subsequently, it has been demonstrated that PAKs
are involved in stimulation of cell proliferation (includ-
ing anchorage-independent growth), stimulation of cell
survival (inhibition of apoptosis), and stimulation of cell
motility, which are all the most prominent hallmarks of
cancer [19]. Each of these three hallmarks has at least
one known target in a well-established signaling path-
way, which is a direct PAK target. In the PAK family,
PAK2 is unique because it is not only activated by binding
with the small G protein complex Cdc42/Rac, but it is also
cleaved and activated by caspase-3 and similar proteases.
After binding to Cdc42/Rac, the autoinhibitory activity of
PAK2 is attenuated, leading to the autophosphorylation
and activation of PAK2 [20-22]. Recent studies have estab-
lished the function of PAK2 in cancer and identified it as
an invasiveness-associated gene which is implicated with
cancer proliferation and survival. For example, Li et al.
[11] revealed that PAK2 was highly expressed in breast
cancer cell lines and breast invasive ductal carcinoma tis-
sue suggesting that highly expressed PAK2 might promote
breast cancer progression and restrain the cell death re-
sponse induced by chemotherapeutic drugs; Siu et al. [10]ctors in gastric cancer
riate P Hazard ratio 95 % confidence interval
2.821 1.312 ~ 6.263
7.292 2.575 ~ 26.327
1.673 0.910 ~ 4.122
3.681 1.274 ~ 11.066
3.624 1.196 ~ 11.228
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in ovarian cancer cell lines and clinical samples of ovarian
cancers compared with normal cell lines and benign ovar-
ian lesions/inclusion cysts. They also found that knock-
down of PAK2 in ovarian cancer cell lines reduced cell
migration and invasion but did not affect cell proliferation
and apoptosis, suggesting that PAK2 and pPAK2 may play
important roles in ovarian carcinogenesis. In line with
these previous findings, our data showed the upregulation
of PAK2 and pSer20PAK2 in gastric cancer tissues, imply-
ing the activation of PAK2 in tumorigenesis of this disease.
Then, our statistical analysis found that the overexpression
of PAK2 and pSer20PAK2 proteins may be associated with
higher tumor depth, greater extent of lymph node metas-
tasis, positive distant metastasis and advanced tumor
stage, suggesting that the activation of PAK2 may be in-
volved in the aggressive tumor progression of gastric can-
cer. More interestingly, the aberrant expressions of PAK2
and pSer20PAK2 proteins were both independent prog-
nostic factors for gastric cancer.
Conclusion
In conclusion, our data suggest for the first time that the
activation of PAK2 may be associated with advanced tumor
progression of gastric cancer. The overexpression of PAK2
and pSer20PAK2 proteins may be recognized as independ-
ent prognostic markers for overall survival, therefore, the
detection of these proteins may be helpful for predicting
clinical outcome for patients with gastric cancer.
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